Transplantation of autologous extracellular vesicles for cancer-specific targeting.
Animals
Apoptosis
Breast Neoplasms
/ pathology
Case-Control Studies
Cell Proliferation
Colorectal Neoplasms
/ pathology
Dogs
Extracellular Vesicles
/ transplantation
Female
Humans
Liver Neoplasms
/ secondary
Male
Mice
Mice, Inbred C57BL
Mice, SCID
Tissue Distribution
Transplantation, Autologous
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
biocompatible nanoparticles
cancer imaging
drug delivery
fluorescence
theranostic agents
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
07
2020
accepted:
11
11
2020
entrez:
27
1
2021
pubmed:
28
1
2021
medline:
17
8
2021
Statut:
epublish
Résumé
Nano- and microsized extracellular vesicles (EVs) are naturally occurring cargo-bearing packages of regulatory macromolecules, and recent studies are increasingly showing that EVs are responsible for physiological intercellular communication. Nanoparticles encapsulating anti-tumor theranostics represent an attractive "exosome-interfering" strategy for cancer therapy.
Identifiants
pubmed: 33500707
doi: 10.7150/thno.51344
pii: thnov11p2034
pmc: PMC7797692
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2034-2047Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: Al.V., M.G., V.M. and P.C. are coinventors of the patent n. IT 102019000007785 filed on May 5th 2019, at the Italian patent office: UIBM.
Références
J Control Release. 2018 Aug 10;283:223-234
pubmed: 29864473
J Mater Chem B. 2019 Apr 21;7(15):2421-2433
pubmed: 32255119
J Transl Med. 2005 Mar 02;3(1):10
pubmed: 15740633
J Transl Med. 2005 Feb 21;3(1):9
pubmed: 15723705
Ann Surg Oncol. 2019 Mar;26(3):894-898
pubmed: 30588559
Am J Transplant. 2020 Jan;20(1):40-51
pubmed: 31319009
J Exp Med. 2002 May 20;195(10):1303-16
pubmed: 12021310
Mol Aspects Med. 2018 Apr;60:1-14
pubmed: 29432782
J Hepatol. 2020 Jan;72(1):156-166
pubmed: 31568800
N Engl J Med. 2015 Jun 11;372(24):2359-62
pubmed: 26061842
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
Phys Med Biol. 1978 Jan;23(1):159-63
pubmed: 635011
Cancer. 2009 Jun 1;115(11):2491-504
pubmed: 19326450
Cells. 2018 Aug 01;7(8):
pubmed: 30071693
J Extracell Vesicles. 2017 Nov 22;6(1):1400370
pubmed: 29209467
J Extracell Vesicles. 2015 Dec 31;4:30087
pubmed: 26725829
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
Nat Methods. 2017 Feb 28;14(3):228-232
pubmed: 28245209
Nat Commun. 2019 Aug 23;10(1):3838
pubmed: 31444335
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Theranostics. 2019 Jan 30;9(4):1015-1028
pubmed: 30867813
J Control Release. 2019 Jan 28;294:165-175
pubmed: 30557650
Nanomedicine. 2018 Jan;14(1):195-204
pubmed: 28982587
J Control Release. 2015 Dec 28;220(Pt B):727-37
pubmed: 26390807
Theranostics. 2019 Aug 9;9(19):5681-5693
pubmed: 31534511
J Extracell Vesicles. 2015 May 14;4:27066
pubmed: 25979354
Vet Comp Oncol. 2016 Dec;14(4):417-446
pubmed: 28530307
Acta Pharmacol Sin. 2017 Jun;38(6):754-763
pubmed: 28392567
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Sci Adv. 2020 Jul 1;6(27):
pubmed: 32937446
Theranostics. 2019 Oct 17;9(26):8001-8017
pubmed: 31754377
J Control Release. 2019 Jul 10;305:194-209
pubmed: 31121278
ACS Nano. 2016 Apr 26;10(4):3886-99
pubmed: 26978483
J Hematol Oncol. 2019 Feb 14;12(1):16
pubmed: 30764882
Gastroenterology. 2005 Jun;128(7):1796-804
pubmed: 15940614
Adv Drug Deliv Rev. 2013 Jan;65(1):36-48
pubmed: 23036225
Clin Cancer Res. 2003 Nov 1;9(14):5113-9
pubmed: 14613988
Nat Rev Mol Cell Biol. 2019 Sep;20(9):509-510
pubmed: 31324871
Int J Nanomedicine. 2015 Feb 02;10:975-99
pubmed: 25678787